Biocon launches haselmeier&rsquos insulin pen in indiazurich, switzerland, november 22, 2011haselmeier has announced that biocon, one of asia&rsquos premier biotechnology companies, has launched insupen® in india. Under the terms of the agreement between the two companies, biocon has world wide distribution rights to insupen®, for use with biocon&rsquos insulin and insulin analogues.
The first launch of the insupen® has taken place with biocon&rsquos basalog® and insugen® insulins.the insupen® is a reusable insulin pen based on haselmeier&rsquos popular ipen technology. It is designed to be easy to use for the patient and provide accurate and reliable dosing. The insupen® is available in 3 attractive colors and is currently custom designed for use with both basalog® and insugen®, thus maximizing patient convenience the insupen® provides diabetic patients an attractive pen with user friendly features at an affordable cost.
Haselmeier is proud to work with biocon, a premier biotechnology companiy, on this important program to develop and supply insupen®and we look forward to a long and successful partnership,&rdquo said volker wirth, director business development & marketing at haselmeier.rakesh bamzai, president, marketing at biocon added &ldquoi am confident that insupen® will be a delight for patients and a value enhancer for all stake holders.&rdquo about haselmeier gmbhhaselmeier is a leading designer and manufacturer of pen and autoinjection systems. The company&rsquos devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world.
For more information visit www.haselmeier.comabout biocon limit edestablished in 1978, biocon limited bse code 532523, nse id biocon, isin id ine376g01013 is india&39s largest biotechnology company by revenue. The group, promoted by ms. Kiran mazumdarshaw, is a fully integrated, innovation driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon&rsquos value chain traverses the entire length of discovery, development and commercialization of novel therapeutics.
With successful initiatives in clinical development, bioprocessing and global marketing, biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have usfda and ema acceptance. Biocon&rsquos robust product offering includes the world&rsquos first pichia based recombinant human insulin, insugen® and india&rsquos first indigenously produced monoclonal antibody biomabegfrtm.www.biocon.com
